Article Text

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
  1. J Smolen1,
  2. R B Landewé2,
  3. P Mease3,
  4. J Brzezicki4,
  5. D Mason5,
  6. K Luijtens6,
  7. R F van Vollenhoven7,
  8. A Kavanaugh8,
  9. M Schiff9,
  10. G R Burmester10,
  11. V Strand11,
  12. J Vencovský12,
  13. D van der Heijde13
  1. 1
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna and 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
  2. 2
    Department of Internal Medicine/Division of Rheumatology and Caphri Research Institute, University Hospital of Maastricht, Maastricht, The Netherlands
  3. 3
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington, USA
  4. 4
    Oddzial Reumatologii ul, Wojewodzki Szpital Zespolony, Elblag, Poland
  5. 5
    Research and Development, UCB Inc, Atlanta, Georgia, USA
  6. 6
    UCB Inc, Brussels, Belgium
  7. 7
    Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
  8. 8
    Division of Rheumatology, University of California, San Diego, California, USA
  9. 9
    University of Colorado, Denver, Colorado, USA
  10. 10
    Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany
  11. 11
    Division of Immunology/Rheumatology, Stanford University, Portola Valley, California, USA
  12. 12
    Institute of Rheumatology, Prague, Czech Republic
  13. 13
    Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  1. Professor J Smolen, Division of Rheumatology, Medical University of Vienna, Vienna A-1090, Austria; josef.smolen{at}meduniwien.ac.at

Footnotes

  • Competing interests: Declared. JS, RBL, PM, RFvV, AK, MS, GRB, VS and DvdH serve as consultants to UCB, Inc. RBL, AK, MS and DvdH receive research funding from UCB, Inc and GRB and JV have received honorarium from UCB, Inc for speaking. DM and KL are employees of UCB, Inc. JB has nothing to disclose.

  • Funding: The RAPID 2 study was fully funded by UCB, Inc.

  • JS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

  • ▸ Additional data are published online only at http://ard.bmj.com/content/vol68/issue6

  • Ethics approval: Ethics committee approval obtained.

View Full Text

Statistics from Altmetric.com

Supplementary materials

Footnotes

  • Competing interests: Declared. JS, RBL, PM, RFvV, AK, MS, GRB, VS and DvdH serve as consultants to UCB, Inc. RBL, AK, MS and DvdH receive research funding from UCB, Inc and GRB and JV have received honorarium from UCB, Inc for speaking. DM and KL are employees of UCB, Inc. JB has nothing to disclose.

  • Funding: The RAPID 2 study was fully funded by UCB, Inc.

  • JS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

  • ▸ Additional data are published online only at http://ard.bmj.com/content/vol68/issue6

  • Ethics approval: Ethics committee approval obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles